HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RNAC
Cartesian Therapeutics, Inc.
There isn't enough reported data to score RNAC yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RNAC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
RNAC's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RNAC PE Valuation
RNAC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RNAC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RNAC's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RNAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2021 | -$20.70 | +$12.90 |
| Q4 2020 | -$20.40 | +$16.20 |
RNAC has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RNAC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
RNAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $78K | -93% |
| Q3 2025 | $452K | +17% |
| Q2 2025 | $298K | -99% |
| Q1 2025 | $1.1M | -81% |
| Q3 2024 | $387K | -94% |
| Q2 2024 | $33.4M | +537% |
| Q1 2024 | $5.8M | -1.7% |
| Q4 2023 | $8.3M | -51% |
RNAC's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -33973% | -31983 points |
| Q4 2025 | -8304% | N/A |
| Q3 2025 | -4661% | -119 points |
| Q2 2025 | -7319% | -7360 points |
| Q1 2025 | -1990% | -1761 points |
| Q3 2024 | -4541% | -4342 points |
| Q2 2024 | 41% | +396 points |
| Q1 2024 | -229% | +81 points |
RNAC's operating margin was −33973% last quarter, down 31983 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RNAC on cash generation, producing positive trailing cash flow while its opponent burns cash.
RNAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$28.2M | -$11.3M |
| Q2 2026 | -$21.4M | -$1.2M |
| Q1 2026 | -$22.2M | +$2M |
| Q4 2025 | -$18.2M | -$10.5M |
| Q3 2025 | -$16.9M | -325% |
| Q2 2025 | -$20.1M | -$4.1M |
| Q1 2025 | -$24.2M | -$7.7M |
| Q4 2024 | -$7.7M | +$15.6M |
RNAC has burned cash in almost every quarter: −$90M over the past year, against −$69M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RNAC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RNAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +448K shares |
| 1 year | +17% | +4.3M shares |
| 3 years | +493% | +25.2M shares |
| 5 years | +798% | +26.9M shares |
RNAC has 30M diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RNAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -7.0x | Net Cash |
| Q3 2022 | -4.1x | Net Cash |
| Q2 2022 | -5.1x | Net Cash |
| Q1 2022 | -8.1x | Net Cash |
RNAC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RNAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.5 | Neutral |
| Stochastic | 16.1 | Oversold |
RNAC's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RNAC PE vs Healthcare Sector
| Metric | RNAC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RNAC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RNAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.83 | 6.9% below |
| 20 week MA | $8.07 | 21% below |
| 50 week MA | $7.57 | 16% below |
| 100 week MA | $10.1 | 37% below |
| 200 week MA | $19.2 | 67% below |
RNAC is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RNAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.7 | $98.1 | +43% |
| 2021 | $98.1 | $107.1 | +9.2% |
| 2022 | $107.1 | $29.4 | -73% |
| 2023 | $29.4 | $20.7 | -30% |
| 2024 | $20.7 | $19.8 | -4.3% |
| 2025 | $19.8 | $6.68 | -66% |
| 2026 YTD | $6.68 | $6.36 | -4.8% |
RNAC has the edge over HIMS on returns for 2026, with the stronger performance.